Clinical TrialsSearch results
Number of results: 230
- Recruitment status
- Title of the study
- Health Condition
- Primary sponsor
- Date of registration
Completed
- Revised Investigator-Initiated Clinical Study of Wearable Assistive Robot for Lower Limbs Controlled Voluntarily by Bioelectric Signals etc.,
(Hybrid Assistive Limb [HAL]-HN01) as a New Medical Device to Delay Progression of Intractable Rare Neuromuscular Diseases
-A Multicenter Randomized Controlled Parallel-Group Study to Evaluate the Short-Term Gait Improvement Effect on Ambulation Disability Caused by Spastic Paraplegia such as HTLV-1-Associated Myelopathy (HAM) etc.- (Study NCY-2001R)
- The target disease condition of this study is ambulation disability caused by spastic paraplegia resulting from HTLV-1-Associated Myelopathy (HAM) according to HAM/TSP diagnostic guidelines (from the 1988 Kagoshima WHO Scientific Council), as well as ambulation disability occurring from chronic monophasic spastic paraplegia similar to HAM resulting from other causes (hereinafter, "Ambulation disability caused by HAM, etc."). Examples of diseases and conditions to be included in chronic monophasic spastic paraplegia are: hereditary spastic paraplegia, traumatic spinal cord injury, spinal vascular disorders, myelitis, cured spinal cord tumors, ossification of posterior longitudinal ligament that is orthopedically stable due to surgeries and allows for the burden of walking, ossification of yellow ligament, and spondylosis as non-traumatic spinal cord injuries, and conditions clinically equivalent to these diseases though its cause cannot be identified as one of the aforementioned.
- Takashi Nakajima
- 2016-08-02
Completed
- Revised Investigator-Initiated Clinical Study of Wearable Assistive Robot for Lower Limbs Controlled Voluntarily by Bioelectric Signals etc.,
(Hybrid Assistive Limb [HAL]-HN01) as a New Medical Device to Delay Progression of Intractable Rare Neuromuscular Diseases
-A Multicenter Randomized Controlled Parallel-Group Study to Evaluate the Short-Term Gait Improvement Effect on Ambulation Disability Caused by Spastic Paraplegia such as HTLV-1-Associated Myelopathy (HAM) etc.- (Study NCY-2001R)
- The target disease condition of this study is ambulation disability caused by spastic paraplegia resulting from HTLV-1-Associated Myelopathy (HAM) according to HAM/TSP diagnostic guidelines (from the 1988 Kagoshima WHO Scientific Council), as well as ambulation disability occurring from chronic monophasic spastic paraplegia similar to HAM resulting from other causes (hereinafter, "Ambulation disability caused by HAM, etc."). Examples of diseases and conditions to be included in chronic monophasic spastic paraplegia are: hereditary spastic paraplegia, traumatic spinal cord injury, spinal vascular disorders, myelitis, cured spinal cord tumors, ossification of posterior longitudinal ligament that is orthopedically stable due to surgeries and allows for the burden of walking, ossification of yellow ligament, and spondylosis as non-traumatic spinal cord injuries, and conditions clinically equivalent to these diseases though its cause cannot be identified as one of the aforementioned.
- Takashi Nakajima
- 2016-08-02
Completed
- Revised Investigator-Initiated Clinical Study of Wearable Assistive Robot for Lower Limbs Controlled Voluntarily by Bioelectric Signals etc.,
(Hybrid Assistive Limb [HAL]-HN01) as a New Medical Device to Delay Progression of Intractable Rare Neuromuscular Diseases
-A Multicenter Randomized Controlled Parallel-Group Study to Evaluate the Short-Term Gait Improvement Effect on Ambulation Disability Caused by Spastic Paraplegia such as HTLV-1-Associated Myelopathy (HAM) etc.- (Study NCY-2001R)
- The target disease condition of this study is ambulation disability caused by spastic paraplegia resulting from HTLV-1-Associated Myelopathy (HAM) according to HAM/TSP diagnostic guidelines (from the 1988 Kagoshima WHO Scientific Council), as well as ambulation disability occurring from chronic monophasic spastic paraplegia similar to HAM resulting from other causes (hereinafter, "Ambulation disability caused by HAM, etc."). Examples of diseases and conditions to be included in chronic monophasic spastic paraplegia are: hereditary spastic paraplegia, traumatic spinal cord injury, spinal vascular disorders, myelitis, cured spinal cord tumors, ossification of posterior longitudinal ligament that is orthopedically stable due to surgeries and allows for the burden of walking, ossification of yellow ligament, and spondylosis as non-traumatic spinal cord injuries, and conditions clinically equivalent to these diseases though its cause cannot be identified as one of the aforementioned.
- Takashi Nakajima
- 2016-08-02
Completed
- Revised Investigator-Initiated Clinical Study of Wearable Assistive Robot for Lower Limbs Controlled Voluntarily by Bioelectric Signals etc.,
(Hybrid Assistive Limb [HAL]-HN01) as a New Medical Device to Delay Progression of Intractable Rare Neuromuscular Diseases
-A Multicenter Randomized Controlled Parallel-Group Study to Evaluate the Short-Term Gait Improvement Effect on Ambulation Disability Caused by Spastic Paraplegia such as HTLV-1-Associated Myelopathy (HAM) etc.- (Study NCY-2001R)
- The target disease condition of this study is ambulation disability caused by spastic paraplegia resulting from HTLV-1-Associated Myelopathy (HAM) according to HAM/TSP diagnostic guidelines (from the 1988 Kagoshima WHO Scientific Council), as well as ambulation disability occurring from chronic monophasic spastic paraplegia similar to HAM resulting from other causes (hereinafter, "Ambulation disability caused by HAM, etc."). Examples of diseases and conditions to be included in chronic monophasic spastic paraplegia are: hereditary spastic paraplegia, traumatic spinal cord injury, spinal vascular disorders, myelitis, cured spinal cord tumors, ossification of posterior longitudinal ligament that is orthopedically stable due to surgeries and allows for the burden of walking, ossification of yellow ligament, and spondylosis as non-traumatic spinal cord injuries, and conditions clinically equivalent to these diseases though its cause cannot be identified as one of the aforementioned.
- Takashi Nakajima
- 2016-08-02
Other
- Efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma: a multicenter randomized controlled trial
- A primary hepatocellular carcinoma case with tumor foci numbering less than 3, each measuring 3 cm or less, Child-Pugh score of 7 or less, ages between 20 and 79 year, and indications for either surgical resection or radiofrequency ablation for the treatment
- Surgery vs. RFA (SURF) trial group
- 2009-04-01
Other
- Efficacy of surgery vs. radiofrequency ablation on primary hepatocellular carcinoma: a prospective cohort study
- A case without informed consent for SURF-RCT among primary hepatocellular carcinoma cases with tumor foci numbering less than 3, each measuring 3 cm or less, Child-Pugh score of 7 or less, ages between 20 and 79 year, and indications for either surgical resection or radiofrequency ablation for the treatment
- Surgery vs. RFA (SURF) trial group
- 2009-04-01
Other
- Japan Shunt Registry of Idiopathic Normal Pressure Hydrocephalus
- Idiopathic Normal Pressure Hydrocephalus
- Study Group for normal pressure hydrocephalus granted by the Ministry of Health, Labor and Welfare of Japan
- 2009-09-01
Other
- Randomized Prospective Trial of Intravesical Bacillus Calmette-Guerin Instillation with Low Dose versus Standard Dose for Transitional Cell Carcinoma of the Urinary Bladder
- Initial or recurrent superficial bladder cancer that cannot be completely resected and carcinoma in situ (CIS) of the bladder.
- Study Group for Low-dose BCG Intravesical Instillation Therapy
- 2007-10-05
Other
- A Multicenter Randomized Controlled Trial to Evaluate the Effect of Adjuvant Chemotherapy using Gemcitabine After Resection of Pancreatic Cancer
- resectable pancreatic cancer
- Study Group for Adjuvant Chemotherapy of Pancreatic Cancer
- 2005-08-05
Other
- Multicenter phase I/II trial of adjuvant combination chemotherapy with gemcitabine and S-1 for pancreatic cancer
- pancreatic cancer
- Study Group for Adjuvant Chemotherapy of Pancreatic Cancer
- 2008-04-01